Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
Wataru Fukuokaya(Jikei University School of Medicine), Shin Egawa, Jun Miki(Jikei University School of Medicine), Yuhei Koike(Jikei University School of Medicine), Masatoshi Tanaka, Yuki Enei(Jikei University School of Medicine), Takafumi Yanagisawa(Jikei University School of Medicine), Mariko Honda(Jikei University School of Medicine), Shunsuke Tsuzuki(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Yuya Iwamoto(Jikei University School of Medicine), Hirokazu Abe(Kameda Medical Center), Yu Oyama(Kameda Medical Center), Shoji Kimura(Jikei University School of Medicine), Hajime Onuma(Jikei University School of Medicine), Fumihiko Urabe(Jikei University School of Medicine)
Cited by 11
Related Papers
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282
Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis
|World Journal of Urology|2019|134
Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
|Clinical Cancer Research|2019|129
Exploiting the message from cancer: the diagnostic value of extracellular vesicles for clinical applications
|Experimental & Molecular Medicine|2019|112